Quote | Silence Therapeutics Plc (NASDAQ:SLN)
Last: | $18.21 |
---|---|
Change Percent: | -0.17% |
Open: | $18 |
Close: | $18.21 |
High: | $18.62 |
Low: | $17.55 |
Volume: | 119,692 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Silence Therapeutics Plc (NASDAQ:SLN)
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Message Board Posts | Silence Therapeutics Plc (NASDAQ:SLN)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...